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Abstract 
Introduction: We investigated the ability of N-hexacosanol, a neurotrophic substance, 
to reverse diabetes-induced cystopathy in the rat.   
Mater ials and methods: Eight-week-old male SD rats were divided randomly into four 
age-matched groups.  In three of these groups, diabetes was induced by streptozotocin 
(50 mg/kg i.p.).  Four weeks after the induction of diabetes, the three groups received 
another four weeks of treatment by vehicle or N-hexacosanol (2, or 8 mg/kg, i.p. every 
day).  The serum glucose and serum insulin levels were determined, and the bladder 
functions were estimated by voiding behavior studies, cystometric studies, and 
functional studies using carbachol and KCl. The participation levels of M2 and M3
Results: Treatment with N-hexacosanol did not alter the rats’ diabetic status, but did 
significantly improve the diabetes-induced dysfunction of the detrusor in a 
dose-dependent manner.  Furthermore, N-hexacosanol significantly reversed the 
up-regulation of muscarinic m
 
receptors were investigated by real-time PCR and immunohistochemical staining.  
Typical H&E staining was also performed.   
2 and m3 receptor mRNAs in STZ-diabetic rats.  
Muscarinic M2 and M3 receptors were localized in detrusor and urothelium, and there 
was no difference between any of the groups in the distribution of muscarinic M2 and 
M3
Conclusion: These results indicate that N-hexacosanol has a beneficial effect on 
hyperreactivity in the diabetic detrusor by ameliorating over-expression of muscarinic 
m
 receptors.   
2 and m3 receptor mRNAs.
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Introduction  
It has been reported that 26-78% of patients with diabetes mellitus have disease-induced 
dysfunction of the lower urinary tract, and diabetic cystopathy is a common 
complication of diabetes mellitus [1- 3].  These urinary tract dysfunctions are induced 
primarily by diabetes-associated neuropathy [1- 3].  Several rodent models have been 
used to investigate type I diabetes [4].  Streptozotocin (STZ), which causes sub-total 
pancreatic islet necrosis, has been widely used to induce insulin-dependent diabetic 
states in experimental animals.  Residual insulin production enables these rats to 
survive without insulin supplementation for extended periods of time.  Thus, 
STZ-induced diabetic rats are widely used to investigate type I diabetes [4].  These rats 
show hyperglycemia, hypoinsulinemia, and inhibited weight gain during feeding.  
Furthermore, significant increases in bladder weight and residual urine volume, 
hypercontractility to carbachol, and up-regulation of muscarinic receptors in the bladder 
dome have been reported in this diabetic model [4-8]. 
The tropical plant Hygrophilia erecta Hochr. has been shown to contain some 
cyclohexenonic long-chain fatty alcohols (N-hexacosanols).  N-hexacosanols have 
neurotrophic effects on cultured neurons from the cerebral cortex. [9, 10].  As 
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N-hexacosanol has a neurotrophic effect, we have reported that N-hexacosanol exerts 
beneficial effects on peripheral neuropathy and cystopathy in streptozotocin-induced 
diabetic rats, and that N-hexacosanol treatment can normalize diabetes-induced 
alterations of motor sciatic nerve conduction [7, 8, 11].  However, the detailed 
mechanisms underlying the action of diabetes-induced cystopathy by this drug remain 
unclear.  In this study, we tried to investigate N-hexacosanol’s ability to reverse 
diabetes-induced cystopathy and the possible mechanism underlying this ability in 
STZ-induced diabetic rats.
 5 
Mater ials and Methods 
Animal model 
All animal experiments were performed in accordance with the guidelines established 
by the Tottori University Committee for Animal Experimentation.  Diabetes was 
induced in 8-week-old male Sprague-Dawley rats (SLC, Shizuoka, Japan) by 
administering an intraperitoneal injection of streptozotocin (STZ) (50 mg/kg) dissolved 
in 0.1 M citrate-phosphate buffer (pH 4.2) [8, 11, 12].  The rats were divided randomly 
into four age-matched groups (n=6-8).  One group was a non-diabetic control (group 
A), and was administered 0.1 M citrate-phosphate buffer (pH 4.2) without 
N-hexacosanol; diabetes was induced in the three others.  Four weeks after the 
induction of diabetes, animals were treated for another four weeks with a vehicle 
(groups A and B) or with N-hexacosanol at a daily dose of 2 or 8 mg/kg for another four 
weeks (groups C and D, respectively).  Two days after the injection of STZ or the 
vehicle, the induction of diabetes was confirmed by measuring urinary glucose with 
Pretest 3aⅡ (Wako Pure Chemical, Osaka, Japan).  In our preliminary study 
demonstrated that N-hexacosanol did not effect on non diabetic rat bladder function 
(data not shown).  In every rat, N-hexacosanol (groups C and D) or vehicle (groups A 
and B) were injected i.p. every day beginning four weeks after the induction of diabetes 
[8, 11, 12].  All of the groups were kept under identical conditions and had access to 
food and drinking water ad libitum.  Eight weeks after the induction of diabetes, the 
rats were subjected to cystometric examination and then sacrificed with an overdose of 
pentobarbital (60 mg, i.p.).  Blood samples were collected from the vena cava, and the 
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bladder dome was removed and placed in Krebs-Henseleit solution.  The blood 
samples and bladder domes were then used for functional, biochemical, and histological 
studies. 
 
Serum glucose and insulin measurement 
Serum glucose concentrations in the experimental rats were measured by the hexokinase 
method (Glucose CⅡ, Wako Pure Chemical, Osaka, Japan), which was carried out 
according to the kit manufacturer’s instructions.  Insulin concentrations were also 
measured by ELISA according to the manufacturer’s instructions (Rat Insulin ELISA, 
Mercodia AB, Uppsala, Sweden). 
 
Voiding behavior studies 
Voiding behavior studies were performed according to methods used in our previous 
study [8].  All rats received water ad libitum from the time they were initially placed 
in the cage.  The parameters of the micturition reflex obtained were micturition 
frequency and total urine output.   
 
Cystometr ic studies 
The cystometric studies were performed according to methods used in our previous 
report [8].  The following parameters were evaluated according to our previous 
reports: bladder capacity, maximum detrusor pressure during voiding, single-voided 
volume, and residual urine volume. 
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Tissue preparation and measurement of contractile force in the bladder   
Functional studies were conducted according to methods used in our previous reports 
[8].  Razor blades were used to cut uniform longitudinal strips of the posterior wall of 
the bladder dome (1.5 x 5 mm).  These muscle strips were mounted in organ baths (25 
ml) containing Krebs-Henseleit solution and were bubbled with 5% CO2 and 95% O2
 
 
(37 ℃ ).  One hook was suspended from a transducer (type 45196A, San-ei 
Instruments, Tokyo, Japan), and the lower hook was fixed to a plastic support leg 
attached to a micrometer (Mitutoyo, Tokyo, Japan).  Changes in the tone of the strips 
were measured isometrically by means of force transducers, and the data were recorded 
on a personal computer (Macintosh G3, Apple Computer) with the use of software 
Chart v 3.6.9 and a PowerLab/16sp data acquisition system (AD Instruments).  
Cumulative concentration-response curves to carbachol and KCl (100 mM) were 
constructed. 
Real-time PCR (quantification of muscar inic m2 and m3
Muscarinic m
 receptor mRNAs) 
2 and m3 receptor mRNAs in the experimental bladder dome were 
measured by real-time PCR methods.  The RNA was purified by RNeasy Mini Kit 
(Qiagen, Valencia, CA) according to the manufacturer’s instructions.  A reverse 
transcriptase (RT) mixture (28 µl) containing 2 µg of total RNA was made and 
incubated at 37 ℃ for 60 min according to a previously reported method [13].  Five 
microliters of the mixture was used for real-time PCR, which was carried out using a 
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LightCycler thermal cycler system with a LightCycler-FastStart DNA Master 
Hybridization Probe according to the manufacturer’s instructions (Roche Diagnostics, 
Tokyo, Japan) [14].  The primers and probe sequences specific to the genes of M2 and 
M3 receptors are shown in Table 1.  The predicted product sizes of M2 and M3
 
 
receptors were 148 bp and 149 bp, respectively.  The primer and probe of the β-actin 
used were from the LightCycler-Primer/Probe Set (rat).  A total of 15 µl of solution 
was used for the sample.  The specificity of the reaction was confirmed by melting 
curve analysis and 2% agarose gel electrophoresis.  The β-actin gene was used as the 
internal standard and analyzed by real-time PCR using the same RT mixture. 
Histological examination of the rat bladder dome 
After fixation, the tissues were embedded in paraffin.  Five micron-thick tissue 
sections were cut from these paraffin blocks.  All of the bladder specimens were 
stained using hematoxylin and eosin (H&E) staining.  The stained tissue sections of 
the experimental bladder dome were viewed at a magnification of X 40-400 under a 
light microscope (BX50, Olympus, Tokyo, Japan) using a digital camera (HC-3000, 
Fujix, Tokyo, Japan).  The serial sections were also subjected to immunohistochemical 
stains for muscarinic M2 and M3 receptors.  Briefly, after sections were deparaffinized, 
they were then reacted overnight with rabbit anti-muscarinic M2 receptor or muscarinic 
M3 receptor polyclonal antibody (Acris Antibodies GmbH, Hiddenhausen, Germany) at 
1:1000 and 1:500 dilutions, respectively.  The specifically bounds of first bound 
antibodies were visualized by Histofine simple stain rat MAX-PO with a Histofine 
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simple stain substrate (Nichirei Co., Tokyo, Japan).  Mayer’s hematoxylin was used for 
counterstaining.  Negative controls were established for each group according to the 
procedure mentioned above, but without the Histofine simple stain rat MAX-PO.  The 
stained tissue sections were viewed at a magnification of X 40-400 under a light 
microscope (BX50, Olympus) using a digital camera (HC-3000, Fujix). 
 
Data analysis 
The ED50 and Emax values were obtained by a Macintosh computer (G3) loaded with 
Chart v3.6.9 software and a PowerLab/16sp data acquisition system.  Contractile data 
were calculated as grams of active force per cross sectional area in square millimeters.  
The cross-sectional area was calculated using the following equation: cross-sectional 
area = weight / (length x 1.05), where 1.05 is the assumed density of the muscle [8].  
The expression of muscarinic m2 and m3
 
 receptor mRNAs was quantified according to 
the expression of β-actin mRNAs in the experimental rat bladder domes.  A statistical 
comparison of differences between groups was performed using analysis of variance 
and Fisher’s multiple comparison tests.  P<0.05 was regarded as the level of 
significance. 
Drugs and chemicals  
3-(15 Hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen 1-one (N-hexacosanol) was 
obtained from Meiji Milk Products Co., Ltd., Tokyo, Japan.  Carbachol was purchased 
from Sigma (St. Louis, MO).  Streptozotocin (STZ) was purchased from Wako Pure 
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Chemical (Osaka, Japan).  All other chemicals were available commercially and of 
reagent grade.
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Results 
General features of the exper imental animals  
The data obtained regarding the general features and serum concentrations of insulin 
and glucose in the experimental animals are shown in Table 2.  The diabetic rats 
treated without N-hexacosanol showed no weight gain and a significant increase in 
bladder weight during the experimental period.  The diabetic rats displayed 
significantly higher serum glucose and lower serum insulin levels than those of the 
control rats.  Treatment with N-hexacosanol (at either 2 or 8 mg/kg) neither increased 
body weight nor reduced serum glucose and insulin levels of the diabetic animals.  
These data agree with our previous reports.  Diabetic rats treated without 
N-hexacosanol showed a significant increase in bladder weight during the initial four 
weeks, and treatment with N-hexacosanol failed to inhibit an additional increase of 
bladder weight. 
 
Voiding behavior studies  
The voiding behavior data and the cystometric results for the experimental animals are 
shown in Table 3.  In the voiding behavior studies, urine production, micturition 
frequency, and single voided volume in the diabetic rats (Group B) were significantly 
larger than that in the control rats (Group A).  Additional treatment with 
N-hexacosanol (at both 2 and 8 mg/kg) had no effect on urine production, single voided 
volume, or micturition frequency.   
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Cystometr ic studies  
In the cystometric studies, the maximum detrusor pressure (Pdet) in the diabetic rats 
(group B) was significantly higher than that in the controls.  The single voided volume 
in the diabetic rats treated with or without N-hexacosanol was markedly higher than that 
of the controls.  The residual urine volume in the diabetic rats (group B) was markedly 
greater than that of the controls.  Although the single voided volume was not altered 
by treatment with N-hexacosanol, these two parameters, i.e., maximum detrusor 
pressure (Pdet) and residual urine, were significantly improved by treatment with the 
high dose of N-hexacosanol. 
 
Measurement of contractile response to carbachol and 100 mM KCl 
The Emax values for the contractile response of the longitudinal muscles to carbachol 
and KCl (100 mM) were determined (Table 4).  Diabetes-induced detrusor 
hyperreactivity by carbachol was ameliorated by N-hexacosanol in a dose-dependent 
manner.  The low-dose (2 mg/kg) treatment with N-hexacosanol tended to improve the 
hyperreactivity of the rat detrusor.  The high-dose (8 mg/kg) treatment with 
N-hexacosanol significantly ameliorated diabetes-induced hyperreactivity of the 
detrusor in the diabetic group.  However, the contractile responses to 100 mM KCl and 
the ED50
 
 values with respect to carbachol were not altered by either the induction of 
diabetes or the N-hexacosanol treatment (Table 4).   
Measurement of muscar inic m2 and m3 receptor mRNAs in the rat bladder dome 
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Table 5 shows the expression of m2 and m3 muscarinic receptor mRNAs in the bladder 
dome.  The expression of both mRNAs was significantly higher in the diabetic group 
(B) than in the control group (A).  N-hexacosanol ameliorated the expression of these 
mRNAs in a dose-dependent manner.  Furthermore, in the control group (group A), the 
expression level of the m3 receptor mRNAs was about 25-fold compared to that of the 
m2 receptor mRNAs; in all other groups, the expression level of the m3 receptor 
mRNAs was higher than that of the m2
 
 receptor (10- to 25-fold). 
Histological examination of rat bladder dome 
Typical H&E staining results obtained from the histological examination are shown in 
Figs. 1 and 2.  Typical H&E and immunohistochemical staining results obtained from 
histological examination are shown in Figs. 1 and 2.  In both muscarinic M2 and M3 
receptors immunohistochemical stainings, immunohistological positive was observed in 
the bladder smooth muscle and urothelium in the rat (Fig. 1 and 2).  In the smooth 
muscle layer, immunohistological positive were seen inside and between the muscle 
bundles.
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Discussion 
 
Latifpour et al. [5] reported increased numbers of muscarinic receptors associated with 
the contractile responses to muscarinic agonists in the bladder dome in STZ diabetic 
rats.   Our observations in this study support their report.  We demonstrated the 
ameliorative effects of N-hexacosanol on diabetes-induced hyperreactivity in the rat 
detrusor.  This may explain why N-hexacosanol rescues damaged peripheral neurons 
[7].  The precise mechanism underlying this effect was unclear, and we suspected that 
N-hexacosanol worked on the muscarinic receptor system.  The increase in maximal 
contractions without changes in the ED50 values due to the potent cholinergic agonist 
carbachol in 8-week STZ-induced diabetic rat detrusor indicates that the number of 
muscarinic receptors increases without any change in receptor affinity in the diabetic 
condition.  Therefore, it is possible that N-hexacosanol could ameliorate detrusor 
hyperreactivity by regulating the expression level of the muscarinic receptors.  In order 
to investigate the possible mechanism underlying this effect, we measured the 
expression levels of muscarinic m2 and m3 receptor mRNAs by real-time PCR.  It is 
well known that both M2 and M3 muscarinic receptors are expressed in the detrusor and 
influence contraction through distinct pathways.  Despite numerous reports concerning 
the effects of diabetes mellitus on the lower urinary tract, little is known about the 
influence of diabetes on cholinergic receptors at the mRNA level.  In a previous study 
using a binding assay, muscarinic receptor levels were reported to be up-regulated in 
diabetic rat bladder domes [5, 6].  The present study demonstrates that the expression of 
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m2 and m3 receptor mRNAs was higher in diabetic rats compared to the controls, and 
that N-hexacosanol ameliorated these increases in the rat detrusor.  The present data 
indicate the possibility that the over-expression of muscarinic m2 and m3 receptor 
mRNAs is related to the hypercontraction of the detrusor in diabetic rats.  Furthermore, 
N-hexacosanol partially normalized this hypercontraction by reducing the expression 
levels of the muscarinic m2 and m3 receptor mRNAs.  Recently, Mansfield et al. 
reported that although 75% and 25% of expressed muscarinic receptors were M2 and 
M3 / M5 receptors, respectively, the expression of m3 receptor mRNAs was 
significantly higher than that of m2 receptor mRNAs in the human detrusor and 
epithelium as measured by quantitative competitive RT-PCR methods [15].  Although 
the stability of muscarinic m2 receptor mRNAs is unclear, this instability may be 
attributable to variation in mRNA translation rates, which are governed by a variety of 
hormonal and cellular events, and/or to mRNA stability [15].  Fraser and Lee reported 
that muscarinic m3 receptor mRNA expression was extremely stable compared to that of 
muscarinic m1
The immunohistochemical staining results obtained from the histological 
studies indicated that muscarinic M
 receptor [16]. 
2 and M3 receptors were expressed in both the 
smooth muscle and urothelium in the control.  The M2 receptor antibody was raised in 
rabbits to a synthetic peptide covalently attached to a carrier protein.  Antibodies to the 
carrier protein could have stained similar epitopes in the tissue which are not specific 
for the receptor subtype.  This is particularly true if the carrier protein is the commonly 
used fusion protein glutathione-S-transferase.  Leaving out the secondary antibody, 
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enzyme conjugate (Histofine MAX-PO) will always produce a negative section even if 
100% of the binding is non-specific and therefore this does not prove that the primary 
antibody is specifically bound specifically to the muscarinic receptor subtype in the 
tissue.  So, in this study, we can not rule out that immunohistological positive findings 
were only specific for the receptor subtype.  There was no difference in distribution 
between any of the groups in this study.  Some reports indicated the existence of 
muscarinic M2 and M3
Recently, Torimoto and associates, as well as the present authors, have reported that 
diabetes induces an increase in maximum detrusor pressure during voiding; this increase 
occurred by urethral dysfunction associated with diabetic neuropathy [8, 19].  From 
our previous and present data, it is possible that N-hexacosanol has the ability not only 
to prevent but also to reverse effects of diabetes-induced urethral dysfunction. 
 receptors in the urothelium [17, 18].  Although the precise role 
of these receptors in the urothelium is unclear, Yoshida and his associates have reported 
that the presence of acetyltransferase immunoreactivity in both the smooth muscle layer 
and in the urothelium suggests that a non-neural cholinergic system is activated in the 
urothelium of the bladder [18].  
As N-hexacosanol’s reversal effects take place according to a mechanism that differs 
from that of insulin [20], it is possible that insulin treatment, if administered 
concomitantly with N-hexacosanol treatment, may prevent or reverse diabetic peripheral 
neuropathy.  However, the detailed mechanism of this preventive effect remains 
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unclear, and warrants further study. 
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Figure legends 
 
Figure 1. H&E and immunohistochemical stainings in the control rat bladder dome. 
The muscarinic M2 and M3
 
 receptors were expressed in the bladder smooth muscle and 
urothelium in the control rats. (x400). 
Figure 2. H&E and immunohistochemical stainings in the diabetic rat bladder dome. 
The muscarinic M2 and M3
 
 receptors were expressed in the bladder smooth muscle and 
urothelium in the diabetic rats. (x400). 
Table 1.  Oligonucleotide pr imers and probes used for amplification of M2 and M3
 
 muscar inic receptors 
  Gene                    Position               Oligonucleotide sequence 5’-3’  
     
 M2
 M
   (primer) forward (1390 – 1409) 5’-CCACTCCAGAGATGACAACT-3’                     
2
 M
   (primer) reverse (1519 – 1537) 5’-GGCTACAACGTTC- TGCTTT-3’ 
3
 M
   (primer) forward (1227 – 1245) 5’-GGACTGTGGATGT- GGAGAG-3’                     
3
 M
   (primer) reverse (1358 – 1375) 5’-CGAGGAGTTGGTGTCAGA 
2
 M
   (probe) forward (1433 – 1460) 5’-CCAACTAGTTCTACAGTGGTACTCGTTGGGGTGT-3’ 
2
 M
   (probe) reverse (1462 – 1494) 5’-XACACATCACCTTTTTG- GGCCTTGGTGACT-3’ 
3
 M
   (probe) forward (1267 – 1284) 5’-CCA- GAAGAGCATGGGTGATGGTGACAACT-3’ 
3
 
  (probe) reverse (1286 – 1325) 5’-XGT- CAGAAGGATTTCACCAAGCTTCCCATCCT-3’ 
 Table 2.  General features of the exper imental rats 
 
          Body Weight (g)    
      8 weeks old 12 weeks old   16 weeks old Bladder weight (g)  Serum glucose (mg/dl)  Serum insulin (µg/l) 
A 242.9 ± 3.0 423.6 ± 5.9 498.8 ± 10.1        0.131 ± 0.006      172.8 ± 13.9    2.39 ± 0.660  
B 246.8 ± 6.4 259.5 ± 17.2 * 231.8 ± 23.5 *      0.264 ± 0.038 *     405.0 ± 54.3 
C 250.4 ± 4.7 251.0 ± 17.0 * 229.0 ± 25.4 *      0.232 ± 0.022 *     314.4 ± 46.9
*    0.17 ± 0.009 *  
 
D 253.3 ± 5.1 257.0 ± 16.1 * 237.0 ± 17.1 *      0.241 ± 0.019 *     364.8 ± 34.3 *    0.16 ± 0.004 * 
*    0.17 ± 0.010 *  
 
A: control rats, B: diabetic rats treated with sham, C: diabetic rats treated with N-hexacosanol (2 mg/kg), and D: diabetic rats treated 
with N-hexacosanol (8 mg/kg).  Data are shown as mean ± SEM of six to eight separated determinations in each group.  *) 
significantly different from A group.  
Table 3.  Voiding behavior studies and cystometrogram data in the exper imental rats 
 
      micturion frequency (/day)  urine production (ml/day) Pdet (cmH2
A  10.8 ± 1.9    10.7 ± 0.7  39.1 ± 3.3  0.39 ± 0.05      0.046 ± 0.007 
O)  single voided volume (ml)   residual urine (ml)   
B 43.9 ± 4.8 * 115.3 ± 13.1 *  52.4 ± 4.6 * 0.69 ± 0.11 *     0.573 ± 0.038 † 
C 49.0 ± 6.3 *  99.9 ± 14.2 *  52.1 ± 4.2 * 0.68 ± 0.11 *     0.220 ± 0.016 ‡ 
D 38.8 ± 6.4 *  97.5 ± 18.9 *  41.6 ± 2.1 ** 0.69 ± 0.11 *     0.207 ± 0.015 ‡ 
 
A: control rats, B: diabetic rats treated with sham, C: diabetic rats treated with N-hexacosanol (2 mg/kg), and D: diabetic rats treated 
with N-hexacosanol (8 mg/kg).  Data are shown as mean ± SEM of six to eight separated determinations in each group.  *) 
significantly different from A group.  **) significantly different from B and C groups. †) significantly different from the other groups.  
‡) significantly different from A and B groups.   
 
Table 4.  Functional studies in the exper imental rats 
 
        Emax (g/mm2)      ED50 (10-7 M)    KCl (g/mm2
A   2.35 ± 0.16   15.7 ± 2.6   1.69 ± 0.14 
)        
B  3.29 ± 0.33*   14.0 ± 2.1   1.70 ± 0.17 
C  2.81 ± 0.26   17.7 ± 2.3   1.70 ± 0.16 
D  2.42 ± 0.18†   21.0 ± 2.4   1.59 ± 0.10 
 
A: control rats, B: diabetic rats treated with sham, C: diabetic rats treated with N-hexacosanol (2 mg/kg), and D: diabetic rats treated 
with N-hexacosanol (8 mg/kg).  Data are shown as mean ± SEM of six to eight separated determinations in each group.  Emax and 
ED50 values are for carbachol.  KCl means contractile force to 100 mM KCl.  *) significantly different from A and D groups.  †) 
significantly different from B and C groups. 
Table 5.  Expression of muscar inic M2 and M3
 
 receptor mRNAs in the bladder dome 
               M2/β-actin (x 10-4)            M3 /β-actin (x 10-4
A   1.99 ± 0.56  46.9 ± 6.2    
)     
B 10.02 ± 3.52* 101.3 ± 18.8†    
C  4.87 ± 1.16**  82.9 ± 14.9‡    
D  3.86 ± 0.93*  61.9 ± 7.5 
 
Expression of muscarinic M2 and M3 receptor mRNAs were normalized with that of  -actin mRNAs.  A: control rats, B: diabetic rats 
treated with sham, C: diabetic rats treated with N-hexacosanol (2 mg/kg), and D: diabetic rats treated with N-hexacosanol (8 mg/kg).  
Data are shown as mean ± SEM of six to eight separated determinations in each group.  *) significantly different from the other groups.  
**) significantly different from A and B groups.  †) significantly different from A and D groups.  ‡) significantly different from A 
group.  


